Meeting
2015 ASCO Annual Meeting
Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102).
Authors
Vinay K. Puduvalli
Ohio State University Comprehensive Cancer Center, Columbus, OH
Vinay K. Puduvalli , Jing Wu , Ying Yuan , Terri S. Armstrong , Morris D. Groves , Jeffrey J. Raizer , Pierre Giglio , Howard Colman , David M. Peereboom , Tobias Walbert , Nicholas George Avgeropoulos , Fabio Massaiti Iwamoto , Marc C. Chamberlain , Nina Paleologos , Karen L. Fink , Ryan Merrell , W. K. Alfred Yung , Mark R. Gilbert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01266031
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2012)
DOI
10.1200/jco.2015.33.15_suppl.2012
Abstract #
2012
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen
Poster
2016 ASCO Annual Meeting
Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.
First Author: Wolfgang Wick
Poster
2015 ASCO Annual Meeting
Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.
First Author: Ashley Ghiaseddin
Poster
2014 ASCO Annual Meeting
Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902).
First Author: Evanthia Galanis